Gemfibrozil is well tolerated in most patients. The most frequent side effects noted in clinical trials are:
Gastrointestinal: Abdominal pain, diarrhea and occasionally nausea in 3-5% of patients.
Less common side effects include:
Skin: Rashes.
Musculoskeletal: Tenderness.
Biochemical changes are uncommon, that include eosinophilia, decreases in the plasma of alkaline phosphatase and occasionally rises in transaminases. Gemfibrozil potentiates the effects of oral anticoagulants and may increase biliary lithogenicity with a predicted long-term increase in the incidence of gallstones.